Research programme: neuropsychiatric disorder therapies - Teva Pharmaceutical Industries/PsychoGenics
Latest Information Update: 09 Apr 2010
At a glance
- Originator Cephalon; PsychoGenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Psychiatric disorders